28,388 Shares in AtriCure, Inc. (NASDAQ:ATRC) Purchased by Harbor Capital Advisors Inc.

Harbor Capital Advisors Inc. acquired a new stake in shares of AtriCure, Inc. (NASDAQ:ATRC - Free Report) in the first quarter, according to the company in its most recent 13F filing with the SEC. The fund acquired 28,388 shares of the medical device company's stock, valued at approximately $916,000. Harbor Capital Advisors Inc. owned 0.06% of AtriCure as of its most recent SEC filing.

A number of other large investors also recently bought and sold shares of ATRC. Johnson Financial Group Inc. raised its position in AtriCure by 1,184.1% during the 4th quarter. Johnson Financial Group Inc. now owns 1,618 shares of the medical device company's stock valued at $49,000 after purchasing an additional 1,492 shares in the last quarter. Heck Capital Advisors LLC purchased a new stake in shares of AtriCure during the 4th quarter worth $60,000. Venturi Wealth Management LLC lifted its stake in shares of AtriCure by 1,337.6% during the 4th quarter. Venturi Wealth Management LLC now owns 2,257 shares of the medical device company's stock worth $69,000 after purchasing an additional 2,100 shares during the last quarter. State of Wyoming lifted its stake in shares of AtriCure by 21.9% during the 4th quarter. State of Wyoming now owns 2,481 shares of the medical device company's stock worth $76,000 after purchasing an additional 446 shares during the last quarter. Finally, Tower Research Capital LLC TRC lifted its stake in shares of AtriCure by 232.7% during the 4th quarter. Tower Research Capital LLC TRC now owns 2,871 shares of the medical device company's stock worth $88,000 after purchasing an additional 2,008 shares during the last quarter. Hedge funds and other institutional investors own 99.11% of the company's stock.

Insider Activity

In other news, insider Vinayak Doraiswamy sold 2,500 shares of AtriCure stock in a transaction dated Wednesday, May 28th. The stock was sold at an average price of $33.44, for a total value of $83,600.00. Following the transaction, the insider now directly owns 73,550 shares in the company, valued at approximately $2,459,512. The trade was a 3.29% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders own 3.50% of the company's stock.

Wall Street Analysts Forecast Growth

A number of research analysts have recently weighed in on the company. Canaccord Genuity Group cut their price objective on AtriCure from $66.00 to $52.00 and set a "buy" rating on the stock in a report on Friday, March 28th. Needham & Company LLC lowered their price objective on AtriCure from $51.00 to $44.00 and set a "buy" rating on the stock in a research note on Wednesday, April 30th. JPMorgan Chase & Co. reduced their target price on AtriCure from $51.00 to $46.00 and set an "overweight" rating on the stock in a research report on Thursday, March 27th. JMP Securities reiterated a "market outperform" rating and issued a $60.00 price objective on shares of AtriCure in a report on Wednesday, April 30th. Finally, UBS Group lowered their target price on AtriCure from $60.00 to $58.00 and set a "buy" rating for the company in a research note on Wednesday, April 30th. One analyst has rated the stock with a hold rating and nine have issued a buy rating to the company. Based on data from MarketBeat, AtriCure presently has an average rating of "Moderate Buy" and a consensus price target of $50.67.

AtriCure Stock Up 2.1%

Shares of NASDAQ ATRC traded up $0.66 during midday trading on Monday, reaching $32.28. 109,060 shares of the company's stock were exchanged, compared to its average volume of 598,345. AtriCure, Inc. has a 52-week low of $18.94 and a 52-week high of $43.11. The stock has a market capitalization of $1.60 billion, a PE ratio of -33.98 and a beta of 1.59. The company has a debt-to-equity ratio of 0.13, a quick ratio of 2.62 and a current ratio of 3.65. The business's fifty day moving average price is $32.53 and its two-hundred day moving average price is $34.54.

AtriCure (NASDAQ:ATRC - Get Free Report) last posted its earnings results on Tuesday, April 29th. The medical device company reported ($0.14) EPS for the quarter, beating the consensus estimate of ($0.25) by $0.11. AtriCure had a negative return on equity of 6.80% and a negative net margin of 9.61%. The company had revenue of $123.62 million during the quarter, compared to analyst estimates of $122.92 million. During the same period in the prior year, the company earned ($0.28) earnings per share. The business's revenue was up 13.5% compared to the same quarter last year. Analysts forecast that AtriCure, Inc. will post -0.6 EPS for the current year.

AtriCure Company Profile

AtriCure, Inc develops, manufactures, and sells devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, Europe, the Asia-Pacific, and internationally. The company offers Isolator Synergy Clamps, single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation, and ablate cardiac tissue with the same device; and the Coolrail device, which enables users to make longer linear lines of ablation.